The glucagon-like peptide family has already produced two transformative molecules in medicine. GLP-1 analogs (semaglutide, liraglutide) have revolutionized the treatment of diabetes and obesity. GLP-2 analogs (teduglutide) have given hope to patients with short bowel syndrome. Now, the emerging research around GLP-3 — the next member of this peptide family — is generating interest among researchers and clinicians exploring the boundaries of peptide therapeutics.
Understanding the GLP Family
The glucagon-like peptides are derived from proglucagon, a precursor protein that is processed differently depending on where it’s produced. In the pancreas, proglucagon is cleaved to produce glucagon. In the intestine and brain, it’s cleaved to produce GLP-1 and GLP-2 — along with other bioactive fragments that are still being characterized.[1]
The success of GLP-1 and GLP-2 as therapeutic targets has intensified research into other proglucagon-derived peptides and their biological activities. GLP-3 represents the frontier of this investigation — an emerging area where preclinical science is beginning to reveal potential applications.
What Early Research Suggests
Research into the broader proglucagon-derived peptide family has identified multiple bioactive fragments beyond GLP-1 and GLP-2 that may have distinct physiological roles. These include potential effects on metabolic regulation and energy homeostasis, intestinal function and gut-brain signaling, immune modulation, and tissue-specific growth and repair mechanisms.
The characterization of these peptides is still in early stages, with much of the published work focused on understanding their receptor interactions, signaling pathways, and tissue distribution.[2]
Why This Matters
The trajectory from GLP-1 discovery to semaglutide (Ozempic/Wegovy) took decades — but the payoff was a class of drugs that has fundamentally changed how we approach metabolic disease. GLP-2’s journey followed a similar path, from discovery to FDA-approved therapy for short bowel syndrome.
If the pattern holds, other proglucagon-derived peptides may eventually yield therapeutic applications we haven’t yet imagined. The field of peptide therapeutics is expanding rapidly, and each new discovery builds on the foundation established by its predecessors.
A Note on Emerging Research
It’s important to be transparent about where the science stands. While GLP-1 and GLP-2 have robust clinical evidence spanning decades, the research on additional proglucagon-derived peptides is earlier-stage. We present this information to keep our readers informed about where the field is heading — not to make clinical claims that aren’t yet supported by completed human trials.
This is exactly the kind of evolving science we’ll continue to track and update as new research is published. Our editorial guidelines commit us to accuracy, transparency, and clear labeling of preliminary vs. established research.
References
- Drucker DJ. “The biology of incretin hormones.” Cell Metabolism. 2006;3(3):153-165.
- Holst JJ. “The physiology of glucagon-like peptide 1.” Physiological Reviews. 2007;87(4):1409-1439.
